相关实验视频

Updated: Jun 17, 2025

Protein Kinase C-delta Inhibitor Peptide Formulation using Gold Nanoparticles

Protein Kinase C-delta Inhibitor Peptide Formulation using Gold Nanoparticles

Published on: March 9, 2019

甲素B-可激活生物活性酸纳米载体用于喘高效免疫疗法

Taiyu Song¹, Lulu Yao¹, Angang Zhu¹

¹Department of Pediatrics, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, People's Republic of China.

International journal of nanomedicine

|August 12, 2024

概括

一种新纳米载体,MPP-Trp,通过调节免疫反应,有效地对抗喘. 这种创新的治疗方法可以减少炎症,并将免疫平衡转向Th1主导型,为喘免疫治疗提供了一个有前途的新途径.

科学领域:

生物技术是生物技术.
免疫学免疫学免疫学
纳米医学是一种纳米医学.

背景情况:

喘是一种慢性炎症性呼吸道疾病,具有重大治疗挑战.
像IALLIPF这样的小麦益胺 (MPP) 具有抗氧化特性.
氨酸 (Trp) 以其抗炎作用而闻名.

研究的目的:

开发和评估一种新的cathepsin B-可激活生物活性纳米载体,PEG-IALLIPF-GFLG-W (MPP-Trp),用于喘免疫治疗.
评估MPP-Trp的抗炎和免疫调节作用.
在喘小鼠模型中研究MPP-Trp的治疗疗效.

主要方法:

使用DLS和TEM进行了MPP-Trp的合成,净化和表征.
通过测量氧化 (NO) 和促炎细胞因子 (TNF-α,IL-6,IL-1β) 来评估抗炎作用.
通过流细胞计,qRT-PCR和ELISA评估了对Th1/Th2细胞的免疫调节作用;治疗作用在小鼠喘模型中进行了研究.

主要成果:

在喘性PBMC中,MPP-Trp显著抑制了NO和促炎细胞因子.
MPP-Trp上调了Th1细胞和下调了Th2细胞,增加了IFN-γ并减少了IL-4,IL-13和IL-5.
在具有良好的生物相容性的小鼠喘模型中,MPP-Trp改善了肺病理.

结论:

MPP-Trp表现出显著的免疫调节作用,将免疫反应转向Th1主导型.
通过减少Th2驱动的炎症,MPP-Trp有效地缓解了OVA诱导的喘.
新型生物活性纳米载体MPP-Trp显示出作为喘免疫治疗的潜在治疗剂的前景.

关键词:

在MPP-Trpp.喘喘是一种生物活性的纳米载体.卡瑟普辛B B的情况这是一种免疫调节剂.

更多相关视频

Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo

Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo

Published on: September 28, 2022

Synthesis and Characterization of Placental Chondroitin Sulfate A plCSA-Targeting Lipid-Polymer Nanoparticles

Synthesis and Characterization of Placental Chondroitin Sulfate A plCSA-Targeting Lipid-Polymer Nanoparticles

Published on: September 18, 2018

相关概念视频

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...

Antiasthma Drugs: Leukotriene Modifiers

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms: